Inclusion Criteria:  Signed informed consent form (ICF) Age 18 to 60 years old (inclusive) as of the date the ICF is signed Diagnosis of RRMS according to the revised McDonald criteria EDSS score of 0.0 to 7.0 (inclusive) In case of participants who are subjected to influenza vaccination by the treating physicians prior to cladribine the first or second cycle of cladribine (cohort 1 + cohort 3), this should be performed at least 4 to 6 weeks before the start of cladribine.  Definition of control group:  Patients with active RRMS treated with cladribine will be compared to sex and age matched control individuals, with RRMS under basic treatment either with interferon beta, glatiramer acetate, dimethyl fumarate or teriflunomide, who provide sample material prior to and 6 to 8 months after routine seasonal influenza vaccination during the same period.  Exclusion Criteria:  Previous treatment with B-cell targeted therapies (e.g., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab) Any previous treatment with alemtuzumab, cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation Medical, psychiatric, cognitive, or other conditions that, in the investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, or to complete the study Patients that receive immunosuppressive treatment for diseases other than MS or that receive long-term corticosteroid treatment Patients that received apheresis procedures 6 weeks prior to vaccination or in-between vaccination and DMT initiation Systemic high dose corticosteroid therapy within 6 weeks prior to vaccination or in-between vaccination and DMT initiation Patients with verified infection by human-immunodeficiency-virus or hepatitis-c-virus Patients with major impairment of the blood coagulation system including therapy with anticoagulants Patients with known chicken egg allergy